|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000039203 |
|
最近更新日期: Date of Last Refreshed on: |
2021-01-18 20:29:17 |
|
注册时间: Date of Registration: |
2020-10-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
【辑】重症医学科血流感染病原微生物易感及预后危险因素分析 |
|
Public title: |
Analysis of pathogenic microbiologic characteristics risk factors and predictors of bloodstream infections in critically ills |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
重症医学科血流感染病原微生物易感预后危险因素分析性研究 |
|
Scientific title: |
Analysis of pathogenic microbiologic characteristics risk factors and predictors of bloodstream infections in critically ills |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
唐艳 |
研究负责人: |
唐艳 |
|
Applicant: |
Tang Yan |
Study leader: |
Tang Yan |
|
申请注册联系人电话: Applicant telephone: |
+86 13518508833 |
研究负责人电话:
Study leader's |
+86 13518508833 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
17518478@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
17518478@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国贵州省贵阳市云岩区贵医街28号 |
研究负责人通讯地址: |
中国贵州省贵阳市云岩区贵医街28号 |
|
Applicant address: |
28 Guiyi Street, Yuyan District, Guiyang, Guizhou, China |
Study leader's address: |
28 Guiyi Street, Yuyan District, Guiyang, Guizhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州医科大学附属医院 |
||
|
Applicant's institution: |
Affiliated hospital of Guizhou Medical University |
||
|
研究负责人所在单位: |
贵州医科大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated hospital of Guizhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020105K |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州医科大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
The ethic committee of the Affiliated Hospital of Gui zhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-09-17 00:00:00 | ||
|
伦理委员会联系人: |
王艺明 |
||
|
Contact Name of the ethic committee: |
Yiming Wang |
||
|
伦理委员会联系地址: |
贵州省贵阳市北京路贵医街28号 |
||
|
Contact Address of the ethic committee: |
28 Guiyi Street, Yuyan District, Guiyang, Guizhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
贵州医科大学附属医院重症医学科 |
||||||||||||||||||||||
|
Primary sponsor: |
The department of Critical Care Medicine of Affiliated hospital of Guizhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵阳市云岩区贵医街28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Guiyi Street, Yuyan District, Guiyang, Guizhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究生补助津贴 |
||||||||||||||||||||||
|
Source(s) of funding: |
Graduate experiment allowance |
||||||||||||||||||||||
|
研究疾病: |
重症医学科血流感染 |
||||||||||||||||||||||
|
Target disease: |
Bloodstream infections |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
探讨重症医学科内血流感染患者血流感染病原微生物分布特点及影响其易感、预后的危险因素,为对病情严重程度早评估、早预警提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the distribution characteristics of pathogenic microorganisms and risk factors affecting the prognosis of patients with bloodstream infection in intensive care unit, so as to provide reference for early evaluation and early warning of the severity of the disease. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①年龄≥18岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients over 18 years old; |
||||||||||||||||||||||
|
排除标准: |
临床资料不全者(包括血常规,降钙素原,凝血功能指标以及肝肾功能指标)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients with incomplete clinical data (including blood routine examination, procalcitonin, coagulation function indicators and liver and kidney function indicators). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-11-01 00:00:00至 To 2021-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-11-01 00:00:00 至 To 2021-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2021年6月;上传到ResMan临床试验公共管理平台, http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In June 2021, it will be uploaded to Resman clinical trial public management platform: http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:使用病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
We use case record form to collect data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |